TY  - JOUR
AU  - Langenberg, Karin P S
AU  - Meister, Michael T
AU  - Bakhuizen, Jette J
AU  - Boer, Judith M
AU  - van Eijkelenburg, Natasha K A
AU  - Hulleman, Esther
AU  - Ilan, Uri
AU  - Looze, Eleonora J
AU  - Dierselhuis, Miranda P
AU  - van der Lugt, Jasper
AU  - Breunis, Willemijn
AU  - Schild, Linda G
AU  - Ober, Kimberley
AU  - van Hooff, Sander R
AU  - Scheijde-Vermeulen, Marijn A
AU  - Hiemcke-Jiwa, Laura S
AU  - Flucke, Uta E
AU  - Kranendonk, Mariette E G
AU  - Wesseling, Pieter
AU  - Sonneveld, Edwin
AU  - Punt, Simone
AU  - Boltjes, Arjan
AU  - van Dijk, Freerk
AU  - Verwiel, Eugene T P
AU  - Volckmann, Richard
AU  - Hehir-Kwa, Jayne Y
AU  - Kester, Lennart A
AU  - Koudijs, Marco M J
AU  - Waanders, Esme
AU  - Holstege, Frank C P
AU  - Vormoor, H Josef
AU  - Hoving, Eelco W
AU  - van Noesel, Max M
AU  - Pieters, Rob
AU  - Kool, Marcel
AU  - Stumpf, Miriam
AU  - Blattner-Johnson, Mirjam
AU  - Balasubramanian, Gnana P
AU  - Van Tilburg, Cornelis M
AU  - Jones, Barbara C
AU  - Jones, David T W
AU  - Witt, Olaf
AU  - Pfister, Stefan M
AU  - Jongmans, Marjolijn C J
AU  - Kuiper, Roland P
AU  - de Krijger, Ronald R
AU  - Wijnen, Marc H W
AU  - den Boer, Monique L
AU  - Zwaan, C Michel
AU  - Kemmeren, Patrick
AU  - Koster, Jan
AU  - Tops, Bastiaan B J
AU  - Goemans, Bianca F
AU  - Molenaar, Jan J
TI  - Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
JO  - European journal of cancer
VL  - 175
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2022-02304
SP  - 311 - 325
PY  - 2022
AB  - iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April 2017 and April 2021, 302 samples from 253 patients were included. Comprehensive molecular profiling including low-coverage whole genome sequencing (lcWGS), whole exome sequencing (WES), RNA sequencing (RNA-seq), Affymetrix, and/or 850k methylation profiling was successfully performed for 226 samples with at least 20
KW  - Adolescent (Other)
KW  - Cancer (Other)
KW  - Child (Other)
KW  - Hereditary (Other)
KW  - Molecular biology (Other)
KW  - Molecular targeted therapy (Other)
KW  - Next-generation sequencing (Other)
KW  - Precision medicine (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36182817
DO  - DOI:10.1016/j.ejca.2022.09.001
UR  - https://inrepo02.dkfz.de/record/181934
ER  -